Metformin in polycystic ovary syndrome

被引:28
作者
Lord, J [1 ]
Wilkin, T
机构
[1] Royal Cornwall Hosp, Peninsula Med Sch, Dept Obstet & Gynaecol, Truro TR1 3LT, England
[2] Univ Med, Derriford Hosp, Peninsula Med Sch, Dept Endocrinol & Metab, Plymouth PL6 8DH, Devon, England
关键词
polycystic ovary syndrome; metformin; ovulation induction; metabolic syndrome;
D O I
10.1097/00001703-200412000-00008
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose of review Metformin has become an established treatment for women with polycystic ovary syndrome, although controversy remains as to how effective it is and in which populations it should be used. This review examines the recent literature in order to ascertain the evidence for the benefits and disadvantages of using metformin in women with polycystic ovary syndrome. Recent findings A Cochrane systematic review and metaanalysis examined the evidence for metformin in treating polycystic ovary syndrome. Since this was published there have been a number of new trials, some of which have been reasonably large involving participants from many different countries. Summary Evidence shows that metformin is effective in inducing ovulation, has some marginal benefit in improving aspects of the metabolic syndrome, improves objective measures of hirsutism, and seems to be effective in both obese and lean indivduals, However, it has significant side effects, and the high levels of effectiveness that were reported by some early trials have not been replicated. Metformin should always be used as an adjuvant to general lifestyle improvements, and not as a replacement for increased exercise and improved diet.
引用
收藏
页码:481 / 486
页数:6
相关论文
共 52 条
[1]   Type 2 diabetes in the young: The evolving epidemic - The International Diabetes Federation Consensus Workshop [J].
Alberti, G ;
Zimmet, P ;
Shaw, J ;
Bloomgarden, Z ;
Kaufman, F ;
Silink, M .
DIABETES CARE, 2004, 27 (07) :1798-1811
[2]  
[Anonymous], MIDDLE E FERTILITY S
[3]  
[Anonymous], FERT ASS TREATM PEOP
[4]  
Balen Adam, 2003, Hum Fertil (Camb), V6 Suppl 1, pS42, DOI 10.1080/1464770312331369263
[5]   Ultrasound assessment of the polycystic ovary: international consensus definitions [J].
Balen, AH ;
Laven, JSE ;
Tan, SL ;
Dewailly, D .
HUMAN REPRODUCTION UPDATE, 2003, 9 (06) :505-514
[6]  
Barbieri R L, 2004, Minerva Ginecol, V56, P63
[7]   Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? [J].
Cheang, KI ;
Nestler, JE .
REPRODUCTIVE BIOMEDICINE ONLINE, 2004, 8 (04) :440-447
[8]   Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: A randomized, double-blind and placebo-controlled trial [J].
Chou, KH ;
Corleta, HV ;
Capp, E ;
Spritzer, PM .
HORMONE AND METABOLIC RESEARCH, 2003, 35 (02) :86-91
[9]   Insulin-lowering agents in the management of polycystic ovary syndrome [J].
De Leo, V ;
la Marca, A ;
Petraglia, F .
ENDOCRINE REVIEWS, 2003, 24 (05) :633-667
[10]  
Dhindsa G, 2004, J Postgrad Med, V50, P140